COVID-19 Antigens Product Range

CodeProduct Description
39501Recombinant SARS-CoV-2 Nucleocapsid Protein lysates expressed in baculovirus expression system using the patented KREX™ functional proteomics technology
39502Recombinant SARS-CoV-2 Spike Protein lysates expressed in baculovirus expression system using the patented KREX™ functional proteomics technology
39503COVID-19 microarray containing full-length, correctly folded and functional human SARS-CoV-2 and antigens from other respiratory viruses including influenza, SARS and MERS
39504High-throughput, high multiplex microtitre plate for COVID-19 diagnostic/surveillance test containing full-length, correctly folded and functional human SARS-CoV-2 and antigens from other respiratory viruses including influenza, SARS and MERS
39505Multiple recombinant Hemagglutinin protein lysates expressed in baculovirus expression system using the patented KREX™ functional proteomics technology
39506Recombinant MERS and recombinant SARS protein lysates expressed in baculovirus expression system using the patented KREX™ functional proteomics technology

Key Applications

Use Sengenics’ correctly folded spike or nucleocapsid COVID-19 antigens for production of a high-affinity vaccine

Development of an antigen-based COVID-19 sero-diagnostic test for patient screening or immunosurveillance purposes

Fundamental research: characterisation of full-length, correctly folded and functional SARS-CoV-2 antigens

List of Proteins

Disease Protein NameProtein Seq. Length (aa)GenBank Accession IDExpression SystemTech
COVID-19SARS-CoV-2-Nucleocapsid protein full length419MN908947.3Baculovirus - insect cellKREX - BCCP
COVID-19SARS-CoV-2-Spike protein full length1273YP_009724390.1Baculovirus - insect cellKREX - BCCP
SARSSARS-CoV-Nucleocapsid protein full length422NP_828858.1Baculovirus - insect cellKREX - BCCP
MERSMERS-CoV-nucleocapsid protein full length413AKQ21082.1Baculovirus - insect cellKREX - BCCP

brochure

Advantages of Sengenics’ COVID-19 Antigens and Tests

Correctly folded antigens lead to better immunogenic response

Since most antibodies are thought to recognise discontinuous epitopes on their target proteins, it’s critical that antigens used in serological assays or presented to B-cells for antibody-based vaccine development are in a natively-folded form. The use of our KREX™ technology for the production of the SARS-CoV-2 antigens will ensure these antigens are correctly folded, preserving all conformational antibody binding sites.

Higher sensitivity and specificity than antibody/RT-PCR-based test

Serological-based tests enable the quantification of IgM and other types of Immunoglobulin. In the case of infectious diseases, IgM is the first antibody produced by the body to fight a new infection. Therefore, our test will overcome the limitations of current rtPCR test. It is also crucial for immunosurveillance purposes, during both the pre- and post-infection periods, particularly for disease management during a pandemic.

SUPPORT

Resources to access our technology

FAQs

Your technical questions - answered

APPLICATIONS

One technology - endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a Functional Proteomics company that leverages its patented KREX technology to discover autoantibody biomarker signatures for prediction of drug response and severe immune-related adverse events (irAEs). KREX can also be used to identify autoantibody biomarkers to diagnose cancer, autoimmune, neurodegenerative or infectious diseases with higher sensitivity and specificity than conventional diagnostic tests. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Copyright 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation LLC. Registered in Delaware, USA no. 5739583 | Sengenics UK Registered in England and Wales no. 12889389